AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17288230
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) with significant restriction of the number of cigarettes smoked per day
Trial: 15248628
Drug: Esmolol 1
RxNorm normalized name: esmolol 10 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 1 mg kg(‐1) min(‐1)
Trial: 8956395
Drug: Lidocaine-clonidine retrobulbar
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine-clonidine retrobulbar block (3-4 mL of 2% lidocaine with clonidine 2 micrograms/kg)
Trial: 8956395
Drug: Lidocaine retrobulbar
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine retrobulbar block (3-4 mL of 2% lidocaine with 1 mL saline)
Trial: 31647836
Drug: Maraviroc 300
RxNorm normalized name: maraviroc 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc 300 mg twice daily (BID) for fifteen days
Trial: 31647836
Drug: Rifabutin 300
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin 300 mg once daily (QD) added on day six
Trial: 20145562
Drug: Cystine (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cystine (700 mg) and theanine (280 mg) supplementation
Trial: 20145562
Drug: Placebo (cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cellulose 950 mg and glutamate 30 mg)
Trial: 19056532
Drug: Infliximab (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (0.8 mg/ml)
Trial: 16837737
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg daily for 15 days plus serratiopeptidase 10 mg daily for 30 days
Trial: 10664830
Drug: Ketamine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (intravenous bolus 0.26 mg/kg followed by infusion of 0.65 mg/kg/hour)
Trial: 8403806
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose ingestion (75 g) in hypertensive patients
Trial: 8403806
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose ingestion (75 g) with potassium chloride supplementation in hypertensive patients
Trial: 8403806
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose ingestion (75 g) in normotensive control subjects
Trial: 22425218
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral anticoagulants (NAs)
Trial: 22425218
Drug: Rivaroxaban (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (40 mg QD)
Trial: 10416732
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation therapy (individual daily sessions of 1 hour for up to 3 months)
Trial: 10416732
Drug: Intensive occupational
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive occupational therapy (control group)
Trial: 7569830
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol replacement therapy plus norethisterone acetate 1 mg per day, oral, cyclically for 12 days monthly
Trial: 2341828
Drug: ESKIMO-3 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESKIMO-3 (15 ml daily for 6 months)
Trial: 2341828
Drug: ESKIMO-3 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESKIMO-3 (30 ml daily for 4 weeks)
Trial: 6376030
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment with energy and carbohydrate restriction
Trial: 19996813
Drug: ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketorolac tromethamine 0.4% (one drop twice a day for 2 weeks)
Trial: 19996813
Drug: artificial tear
RxNorm normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: artificial tear solution (placebo, used for 2 weeks)
Trial: 18004596
Drug: Tolterodine 1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 1-2 mg
Trial: 18004596
Drug: Imipramine 25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 25-50 mg
Trial: 10784228
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg nateglinide (single oral dose, given 20 min prior to IGTT)
Trial: 8769510
Drug: L-arginine hydrochloride
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine hydrochloride infusion (0.5 g/kg for 30 minutes)
Trial: 3902588
Drug: Cimetidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (200 mg at lunch, 400 mg at bedtime)
Trial: 31244692
Drug: Robin (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robin (16 weekly individual sessions + a minimum of 4 family sessions)
Trial: 31244692
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (active control group)
Trial: 22851072
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion with TCI vein pump (Group B)
Trial: 22851072
Drug: Remifentanil vein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil vein infusion with PCA pump (Group C)
Trial: 10649262
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (oral cancer screening)
Trial: 1535816
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms HBs antigen vaccine
Trial: 1535816
Drug: Other hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other hepatitis B vaccine
Trial: 6150660
Drug: 2.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg ketamine intravenously
Trial: 6150660
Drug: 5.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg/kg thiopental intravenously
Trial: 23569301
Drug: Cetuximab plus
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab plus chemotherapy (FOLFIRI or mFOLFOX6)
Trial: 23569301
Drug: Cetuximab plus
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab plus chemotherapy (FOLFIRI or mFOLFOX6) with resection of liver metastases
Trial: 23569301
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone without resection
Trial: 21860843
Drug: Investigational drug
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug (seven doses)
Trial: 10952804
Drug: Endoscopic haemostasis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic haemostasis using single-modality treatments (injection agents such as epinephrine, sclerosants, thrombogenic substances, or thermal therapies)
Trial: 10952804
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy involving injection and thermal techniques
Trial: 6375465
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg buprenorphine after bupivacaine
Trial: 23023905
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid supplementation (3 capsules per day: eicosapentaenoic acid 1,548 mg; docosahexaenoic acid 828 mg; other omega-3 fatty acids 338 mg)
Trial: 23023905
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (sunflower oil 2,100 mg)
Trial: 19778673
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention (PCI) + Optimal medical therapy (OMT)
Trial: 17536129
Drug: Cherries (280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cherries (280 g, 4.5 mmol TE AOC)
Trial: 9733153
Drug: EPA and
RxNorm normalized name: Norwegian Cod Liver Oil With EPA and DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA and DHA ethyl esters (2.04 g EPA and 1.4 g DHA)
Trial: 9733153
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (4 g/day)
Trial: 2256489
Drug: ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ethinyl estradiol (0.035 mg)‐norethindrone (0.40 mg)
Trial: 2256489
Drug: ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ethinyl estradiol (0.030 to 0.040 mg)‐levonorgestrel (0.050 to 0.125 mg)
Trial: 2256489
Drug: non‐oral‐contraceptive group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non‐oral‐contraceptive group
Trial: 23522152
Drug: Antibiotic exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic exposure based on clinical presentation of UTI, pyuria, and procalcitonin (PCT) levels.
Trial: 9086420
Drug: PGE2 gel
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 gel and membrane stripping
Trial: 9086420
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel and membrane stripping
Trial: 9086420
Drug: PGE2 gel
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 gel and no membrane stripping
Trial: 9086420
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel and no membrane stripping
Trial: 21672204
Drug: Multivitamin-mineral supplement
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin-mineral supplement
Trial: 4057126
Drug: Psychological group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological group treatment aimed at weight reduction, improvement of stress coping, and reduction of salt‐intake, conducted over 16 therapy sessions by trained lay therapists.
Trial: 31404055
Drug: Control TDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control TDR (ProDisc-L or Charité)
Trial: 22686512
Drug: Bupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine with adrenaline (40 mL, 2.5 mg/mL bupivacaine and 5 μg/mL adrenaline)
Trial: 22686512
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (40 mL, 0.9%)
Trial: 20491047
Drug: Topical mydriasis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mydriasis
Trial: 16232082
Drug: Isotretinoin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin (0.5 mg/kg per day)
Trial: 12090747
Drug: Low-molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular weight heparin dalteparin
Trial: 10194091
Drug: Testosterone enanthate,
RxNorm normalized name: Testosterone Enanthate, enanthate 200 mg/mL intramuscular solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate, 300 mg i.m. every 3 weeks for 6 months
Trial: 10194091
Drug: Testosterone administration
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone administration for 1 year
Trial: 7761078
Drug: Methotrexate (7.5‐10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (7.5‐10 mg weekly)
Trial: 7761078
Drug: Other therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other therapies (im. gold 50 mg weekly or per os steroid max. 10 mg daily)
Trial: 27892891
Drug: Atorvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (80 mg loading dose within 18 hours before surgery, followed by 40 mg maintenance dose starting at least 12 hours after surgery for 7 days)
Trial: 27892891
Drug: Placebo (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (80 mg loading dose within 18 hours before surgery, followed by placebo maintenance dose)
Trial: 21245790
Drug: Sham spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham spinal manipulation therapy (12 treatments over 1 month)
Trial: 21245790
Drug: Spinal manipulation
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulation therapy (12 treatments over 1 month, no maintenance)
Trial: 21245790
Drug: Spinal manipulation
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulation therapy with maintenance (12 treatments over 1 month, maintenance every 2 weeks for 9 months)
Trial: 11427783
Drug: Exercise dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise dose
Trial: 8183099
Drug: 15N-alanine infusion
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15N-alanine infusion
Trial: 30954200
Drug: Unna's boot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unna's boot (compression therapy)
Trial: 30954200
Drug: Noncompression therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncompression therapy (conventional dressing)
Trial: 16836503
Drug: 1 microg
RxNorm normalized name: Alpha 1 microglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microg low dose test (LDT)
Trial: 16836503
Drug: 250 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 microg standard dose test (SDT)
Trial: 10823311
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (3 g/d) and Vitamin E (1500 IU/d) for 8 days
Trial: 8900501
Drug: Tiaprofenic acid
RxNorm normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiaprofenic acid (TA) 4.2 +/- 0.5 mg/kg orally in a single dose
Trial: 1710489
Drug: ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) as salvage treatment
Trial: 6512981
Drug: Fosfomycin (FOM)
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin (FOM) administered orally at doses of 50 to 100 mg/kg/day for children and 3 g/day for adults for 5 days.
Trial: 6512981
Drug: Fosfomycin (FOM)
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin (FOM) treatment.
Trial: 26197776
Drug: 5‐HT₃ receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HT₃ receptor antagonist with dexamethasone and aprepitant
Trial: 26197776
Drug: 5‐HT₃ receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HT₃ receptor antagonist with dexamethasone
Trial: 24724983
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg misoprostol sublingually and 20 IU oxytocin intravenously
Trial: 24724983
Drug: 20 IU
RxNorm normalized name: Calcium/Phosphorus/Vitamin D 105 MG-81 MG-120 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 IU of intravenous oxytocin alone
Trial: 9731852
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 intracervical gel (Prepidil)
Trial: 7994450
Drug: Intensified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified treatment aiming at a blood pressure < or = 80 mmHg diastolic (group A)
Trial: 7994450
Drug: Unchanged therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unchanged therapy (group B)
Trial: 7994450
Drug: Intensified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified treatment (group A)
Trial: 25012806
Drug: Transcervical 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcervical 30 mL Foley balloon (FB)
Trial: 25012806
Drug: Transcervical 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcervical 60 mL Foley balloon (FB)
Trial: 25012806
Drug: Transcervical 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcervical 30 mL or 60 mL Foley balloon (FB)
Trial: 21996929
Drug: Occupational inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational inhalation exposure to carbon black (CB)
Trial: 11021769
Drug: Pivagabine (1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivagabine (1800 mg/day for 7 days)
Trial: 9167761
Drug: Etoposide at
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide at a dose of 50 mg/d
Trial: 9167761
Drug: Etoposide at
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide at a dose of 50 mg/d with G-CSF
Trial: 8490006
Drug: Calcium (165
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (165 mg Ca as CaCl2) added to a hamburger meal
Trial: 8490006
Drug: Calcium (165
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (165 mg Ca as CaCl2) added to a wheat roll
Trial: 26786573
Drug: 30,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30,000 IU vitamin D3 once weekly for 8 weeks
Trial: 17879948
Drug: Intranasal IM862
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal IM862 daily for 6 months or until disease progression.
Trial: 17879948
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 6 months or until disease progression.
Trial: 9819037
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of recombinant activated factor VII (rFVIIa) targeting a factor VII level of 10 IU/ml
Trial: 9819037
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of recombinant activated factor VII (rFVIIa)
Trial: 9819037
Drug: Parallel infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parallel infusion of heparin, saline or dextrose‐saline
Trial: 1111368
Drug: Morphine-nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine-nitrous oxide anesthesia (2 mg/kg morphine and 70% nitrous oxide in oxygen)
Trial: 31775404
Drug: Parecoxib sodium
RxNorm normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib sodium (PS) 40 mg administered 30 minutes before incision, 12 hours after THA, and every 12 hours for 2 days postoperatively
Trial: 19791828
Drug: Saxagliptin 2.5
RxNorm normalized name: sAXagliptin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 2.5 or 5 mg once daily
Trial: 19791828
Drug: Saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5 mg once daily plus metformin
Trial: 19791828
Drug: Saxagliptin 2.5
RxNorm normalized name: sAXagliptin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 2.5 or 5 mg once daily added to metformin, glyburide, or a thiazolidinedione
Trial: 15373926
Drug: Bioadhesive tablet
RxNorm normalized name: urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioadhesive tablet 100 mg
Trial: 15373926
Drug: Bioadhesive tablet
RxNorm normalized name: urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioadhesive tablet 50 mg
Trial: 15373926
Drug: Oral gel
RxNorm normalized name: Oral Gel
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral gel (375 mg, 3 times a day)
Trial: 11740230
Drug: NaCl therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl therapy (2 mmol/kg/d for 7 days)
Trial: 11740230
Drug: NaHCO3 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NaHCO3 therapy (2 mmol/kg/d for 7 days)
Trial: 9386652
Drug: AC-17 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC-17 (300 mg on days 1-2, 150 mg on day 3)
Trial: 7970686
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (rest and analgesia)
Trial: 18445362
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg once daily for 9 weeks
Trial: 12515743
Drug: 6-methylprednisolone (6‐MP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-methylprednisolone (6‐MP; 1 mg/kg BID for 2 days)